New HPV vaccine provides wider protection

An investigational 9-valent vaccine against human papillomavirus (9vHPV) had an efficacy of nearly 97% against cervical, vulvar, and vaginal disease associated with HPV types 31, 33, 45, 52, and 58 and a similar efficacy against disease associated with HPV types 6, 11, 16, and 18 as a quadrivalent HPV (qHPV) vaccine, in a randomized trial including 14 215 women aged 16 to 26 years. Compared with current HPV vaccines, which protect against 70% of cervical cancers, 9vHPV has the potential to prevent 90% of cervical cancers.